FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2925070005> ?p ?o ?g. }

• W2925070005 abstract "Sphingosine kinases 1 and 2 (SK1 and SK2) are proto-oncogenic isozymes expressed in many human tumors and associated with chemoresistance and poor prognosis. They are well-recognized therapy targets and their inhibition was shown to induce tumor volume reduction and chemosensitization in multiple cancer models. Oncogenic signaling is extremely complex and often cross-regulated. Designing molecular therapies and their combinations requires rational approaches to avoid redundant targeting or developing resistance. In this study, we have performed RNA transcriptome microarray analysis of two breast and two prostate metastatic cancer cell lines treated with siRNAs targeting SK1 or SK2. In prostate cancer cell lines SK1 knockdown (KD) has significantly changed expression of several genes including downregulation of NSUN2, G3BP2 and upregulation of ETS1. SK2 KD also affected expression of multiple genes including downregulation of CAPZA1 NSUN3 and ADPGK and upregulation of VDAC1, IBTK, ETS1, and MKNK2. Similarly, in breast cancer cells SK1 KD led to downregulation of NSUN2, NFATC3, CDK2, and G3BP2 and upregulation of GTF2B, TTC17, and RAB23. SK2 KD in breast cancer cells has decreased expression of ITGAV and CAPZA1 and increased expression of GTF2B and ST13. Gene-set enrichment analysis of known biochemical pathways showed that in prostate and breast cell lines SKs KD have altered multiple pathways. SK1 KD altered chromatin assembly, regulation of G1/S transition and mitosis, Wnt and MAP kinase signaling and cell motility. SK2 KD altered RAS protein signal transduction, regulation of MAP kinase and serine/threonine kinase activity, cell motility, small GTPase mediated signal transduction and phosphatidylinositol 3-kinase (PI3K) signaling. Through genome-wide microarray analysis, we have identified important molecular pathways affected by SK1 and SK2 KD. It appears that while KD of both genes leads to a decrease in individual pro-tumorigenic genes, there is a universal cellular response resulting in upregulation of several known pro-survival and pro-tumorigenic pathways such as MAPK, RAS, and PI3K, which may mediate cancer resistance to anti-SKs therapies. Our data point out to the potential advantage of certain molecular therapy combinations in targeting prostate and breast cancer. Further signaling studies are required to confirm the individual involvement of identified pathways." @default.
• W2925070005 created "2019-04-01" @default.
• W2925070005 creator A5015195367 @default.
• W2925070005 creator A5045355425 @default.
• W2925070005 creator A5045556095 @default.
• W2925070005 creator A5088971353 @default.
• W2925070005 date "2019-03-27" @default.
• W2925070005 modified "2023-10-02" @default.
• W2925070005 title "Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting" @default.
• W2925070005 cites W123717634 @default.
• W2925070005 cites W1974318989 @default.
• W2925070005 cites W1993449698 @default.
• W2925070005 cites W2003007879 @default.
• W2925070005 cites W2004929000 @default.
• W2925070005 cites W2016168519 @default.
• W2925070005 cites W2017180312 @default.
• W2925070005 cites W2018146992 @default.
• W2925070005 cites W2024372331 @default.
• W2925070005 cites W2025671438 @default.
• W2925070005 cites W2027574861 @default.
• W2925070005 cites W2035618305 @default.
• W2925070005 cites W2039461396 @default.
• W2925070005 cites W2074284399 @default.
• W2925070005 cites W2081098333 @default.
• W2925070005 cites W2092378610 @default.
• W2925070005 cites W2109972881 @default.
• W2925070005 cites W2132599961 @default.
• W2925070005 cites W2147245292 @default.
• W2925070005 cites W2148708580 @default.
• W2925070005 cites W2170400518 @default.
• W2925070005 cites W2345133451 @default.
• W2925070005 cites W2591284963 @default.
• W2925070005 cites W2676547495 @default.
• W2925070005 cites W2734714741 @default.
• W2925070005 cites W2735902187 @default.
• W2925070005 cites W2767528129 @default.
• W2925070005 cites W2782251465 @default.
• W2925070005 cites W2789673689 @default.
• W2925070005 cites W2883527677 @default.
• W2925070005 cites W2896525919 @default.
• W2925070005 doi "https://doi.org/10.3389/fphar.2019.00303" @default.
• W2925070005 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6445839" @default.
• W2925070005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30971929" @default.
• W2925070005 hasPublicationYear "2019" @default.
• W2925070005 type Work @default.
• W2925070005 sameAs 2925070005 @default.
• W2925070005 citedByCount "17" @default.
• W2925070005 countsByYear W29250700052020 @default.
• W2925070005 countsByYear W29250700052021 @default.
• W2925070005 countsByYear W29250700052022 @default.
• W2925070005 countsByYear W29250700052023 @default.
• W2925070005 crossrefType "journal-article" @default.
• W2925070005 hasAuthorship W2925070005A5015195367 @default.
• W2925070005 hasAuthorship W2925070005A5045355425 @default.
• W2925070005 hasAuthorship W2925070005A5045556095 @default.
• W2925070005 hasAuthorship W2925070005A5088971353 @default.
• W2925070005 hasBestOaLocation W29250700051 @default.
• W2925070005 hasConcept C104317684 @default.
• W2925070005 hasConcept C127561419 @default.
• W2925070005 hasConcept C137620995 @default.
• W2925070005 hasConcept C170493617 @default.
• W2925070005 hasConcept C173396325 @default.
• W2925070005 hasConcept C2776596873 @default.
• W2925070005 hasConcept C2777550365 @default.
• W2925070005 hasConcept C2777700496 @default.
• W2925070005 hasConcept C2778703144 @default.
• W2925070005 hasConcept C2779251935 @default.
• W2925070005 hasConcept C502942594 @default.
• W2925070005 hasConcept C54355233 @default.
• W2925070005 hasConcept C55493867 @default.
• W2925070005 hasConcept C62478195 @default.
• W2925070005 hasConcept C81885089 @default.
• W2925070005 hasConcept C86803240 @default.
• W2925070005 hasConcept C95444343 @default.
• W2925070005 hasConceptScore W2925070005C104317684 @default.
• W2925070005 hasConceptScore W2925070005C127561419 @default.
• W2925070005 hasConceptScore W2925070005C137620995 @default.
• W2925070005 hasConceptScore W2925070005C170493617 @default.
• W2925070005 hasConceptScore W2925070005C173396325 @default.
• W2925070005 hasConceptScore W2925070005C2776596873 @default.
• W2925070005 hasConceptScore W2925070005C2777550365 @default.
• W2925070005 hasConceptScore W2925070005C2777700496 @default.
• W2925070005 hasConceptScore W2925070005C2778703144 @default.
• W2925070005 hasConceptScore W2925070005C2779251935 @default.
• W2925070005 hasConceptScore W2925070005C502942594 @default.
• W2925070005 hasConceptScore W2925070005C54355233 @default.
• W2925070005 hasConceptScore W2925070005C55493867 @default.
• W2925070005 hasConceptScore W2925070005C62478195 @default.
• W2925070005 hasConceptScore W2925070005C81885089 @default.
• W2925070005 hasConceptScore W2925070005C86803240 @default.
• W2925070005 hasConceptScore W2925070005C95444343 @default.
• W2925070005 hasLocation W29250700051 @default.
• W2925070005 hasLocation W29250700052 @default.
• W2925070005 hasLocation W29250700053 @default.
• W2925070005 hasLocation W29250700054 @default.
• W2925070005 hasLocation W29250700055 @default.
• W2925070005 hasOpenAccess W2925070005 @default.
• W2925070005 hasPrimaryLocation W29250700051 @default.
• W2925070005 hasRelatedWork W1970171722 @default.
• W2925070005 hasRelatedWork W2042963083 @default.

• next